Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai(Peking University), Keith T. Flaherty(Cancer Research Center), Yoshiyasu Umeda(Saitama Medical University), Ryan J. Sullivan(Dana-Farber Cancer Institute), Genevieve M. Boland(Harvard University), Mario Mandalà(University of Perugia), Christoffer Gebhardt(Universität Hamburg), Seungyeon Jung(Vanderbilt University Medical Center), Lu Si(Peking University), Alexander M. Menzies(The University of Sydney), Douglas B. Johnson(Vanderbilt University Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriele Madonna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mariaelena Capone(Istituto di Chimica Biomolecolare), Serigne Lo(The University of Sydney), Dominika Dulak(University of Pittsburgh Medical Center), Charlotte Grieco(Royal Marsden NHS Foundation Trust), Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Lucia Festino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ruth Plummer(National Health Service), Benjamin C. Park(Vanderbilt University Medical Center), Andrew J.S. Furness(Cancer Research UK), Eleonora Bongiovanni(University of Turin), Yana G. Najjar(UPMC Hillman Cancer Center), Paolo D. d’Arienzo(Royal Marsden NHS Foundation Trust), Pietro Quaglino(Department of Medical Sciences), Paul Lorigan(Manchester Academic Health Science Centre), Dai Ogata(Unknown), A. P. Williamson(The Christie NHS Foundation Trust), Georgina V. Long(The University of Sydney), Shaheen Ahmed(Newcastle University), Umberto Santaniello(University of Turin), Aleigha Lawless(Massachusetts General Hospital), Yasuhiro Nakamura(University of Tsukuba), Andrew Haydon(The Alfred Hospital), Jun Guo(Hebei Medical University), Rebecca Lee(Broughton Hospital), Caili Li(Peking University), Avinash Gupta(ITM University), Juliane A. Czapla(Massachusetts General Hospital), Rebecca Johnson(Royal North Shore Hospital), Naoya Yamazaki(Tokyo National Hospital), Florentia Mina(Royal Marsden NHS Foundation Trust), Martina Ubaldi(University of Perugia)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k